Relapsing and Evolving Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Induced by Nivolumab in a Patient With Hodgkin’s Lymphoma in Remission (P1-9.019)

BIANCA ETELVINA OLIVEIRA; LUIZA VILLARIM; JOSE FELIPE FERNANDES; Davi Guerra; DANIEL LIMA JUNIOR; Ana Clara Rodrigues; FRANCISCO CARVALHO; Jeanina Dionizio; Fernando Melo Neto; LUCIANO NASCIMENTO JUNIOR

doi:10.1212/wnl.0000000000217619

June 9, 2026Neurology

Relapsing and Evolving Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Induced by Nivolumab in a Patient With Hodgkin’s Lymphoma in Remission (P1-9.019)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This case aims to illustrate the occurrence of CIDP associated with Nivolumab treatment in a patient with Hodgkin’s lymphoma.
Descriptive case report detailing the patient's clinical history and treatment
Monitoring of electrodiagnostic changes over the course of therapy
Assessment of relapsing symptoms following Nivolumab administration.
CIDP developed after 1.5 years of Nivolumab therapy
The patient exhibited an evolving electrodiagnostic profile
Symptoms presented a relapsing course, indicating potential complications of the treatment.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Case report describes CIDP development after Nivolumab therapy in a patient with Hodgkin’s lymphoma, suggesting potential link.

Abstract

To describe a case of CIDP with an evolving electrodiagnostic profile and a relapsing course that was manifested after 1.5 years of Nivolumab therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

OLIVEIRA et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055f2c https://doi.org/10.1212/wnl.0000000000217619

View at Publisher

Ask AI

Bookmark

Share

Relapsing and Evolving Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Induced by Nivolumab in a Patient With Hodgkin’s Lymphoma in Remission (P1-9.019)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Relapsing and Evolving Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Induced by Nivolumab in a Patient With Hodgkin’s Lymphoma in Remission (P1-9.019)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading